Doctronic CEO: 20M AI medical consultations, prescription renewals in Utah, and the race to be the AI doctor

Summary

Doctronic has logged 20 million AI medical consultations across 2 million patients since launching in September 2023, positioning itself as the largest direct-to-consumer AI doctor platform in the US. The company draws 100,000 to 150,000 site visits per week, primarily through organic search, and reports usage patterns approaching weekly active engagement for a significant share of its user base.

Matt, Doctronic's co-founder and CEO, is a serial entrepreneur with 25 years of startup experience, including an earlier e-commerce unicorn. His co-founder is a practicing physician. The cap table includes Tusk Ventures, the regulatory strategy firm known for navigating Uber's city-by-city expansion, and Fei-Fei Li, signaling both technical credibility and an expectation of sustained regulatory friction.

The Utah Milestone

The company's most consequential development is a newly announced partnership with the Utah AI Learning Lab, under which Doctronic's AI is legally permitted to renew prescriptions for Utah residents without physician oversight. This makes Doctronic, by its own account, the first AI system licensed to practice medicine in the United States. The arrangement operates within Utah's regulatory sandbox for AI, which carves out exemptions from state laws restricting the practice of medicine to licensed physicians.

Outside Utah, the AI stops short of practicing medicine. It produces differential diagnoses across up to four conditions, generates corresponding treatment plans, and prepares documentation patients can bring to their own physicians or to Doctronic's telehealth doctors. Those physicians are licensed across all 50 states and available 24/7.

Regulatory Roadmap

Matt views the Utah model as replicable. Several other states operate AI regulatory sandboxes, and Doctronic is in active discussions with them. The state-by-state structure mirrors how medical licensing has always worked in the US, and the company is deliberately pursuing expansion through that framework rather than waiting on federal preemption. The near-term strategy in less permissive states relies on a hybrid model where AI handles intake, diagnosis preparation, and documentation, while licensed physicians conduct video visits and make final clinical decisions.

Efficiency and NPS

Doctronic reports a 10x productivity gain for its human physicians when working alongside the AI, which pre-processes patient history and narrows the diagnostic field before the doctor engages. NPS scores for the AI marginally exceed those for Doctronic's human doctors, a result Matt attributes to the AI's availability, patience, and information retention rather than any claim that it replicates the depth of a physician relationship.

Matt draws a clear line between routine, high-volume interactions such as prescription renewals, antibiotic decisions, and common symptom triage, which he believes AI can and should own, and complex specialist or chronic condition management, where human judgment remains essential. The appendicitis case he cites, where the AI correctly flagged an imminent rupture and directed a patient to the ER, illustrates both the system's diagnostic range and its appropriate scope boundaries.

Market Context

An estimated 20% of ChatGPT traffic is already health-related, underscoring broad consumer appetite for AI-assisted medical guidance. General-purpose LLMs decline to practice medicine and are constrained by liability design, creating a structural gap that Doctronic is explicitly built to fill. The average American sees a primary care doctor three times a year against a backdrop of a well-documented physician shortage, and no segment of that system is more undersupplied or more resistant to routine work than primary care prescription management.